Liên Minh Châu Âu - Tiếng Ý - EMA (European Medicines Agency)

astrazeneca ab - roflumilast - malattia polmonare, ostruttiva cronica - farmaci per le malattie respiratorie ostruttive, - daxas è indicato per il trattamento di mantenimento di grave malattia polmonare ostruttiva cronica (copd) (fev1 post-broncodilatatore meno del 50% preveduto) associata a bronchite cronica in pazienti adulti con una storia di esacerbazioni frequenti come add-on per trattamento broncodilatatore.

Liên Minh Châu Âu - Tiếng Ý - EMA (European Medicines Agency)

astrazeneca ab - fulvestrant - neoplasie al seno - terapia endocrina, anti-estrogeni - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. in pre - o perimenopausal donne, il trattamento di combinazione con palbociclib, dovrebbe essere combinato con un rilascio dell'ormone luteinizzante (lhrh) agonista.

Liên Minh Châu Âu - Tiếng Ý - EMA (European Medicines Agency)

astrazeneca ab - a/darwin/9/2021 (h3n2) - like strain (a/norway/16606/2021, medi 355293) / a/victoria/2570/2019 (h1n1)pdm09 - like strain (a/victoria/1/2020, medi 340505) / b/austria/1359417/2021 - like strain (b/austria/1359417/2021, medi 355292) / b/phuket/3073/2013 - like strain (b/phuket/3073/2013, medi 306444) - influenza, umano - vaccini contro l'influenza, influenza, vivo attenuato - prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. l'uso di fluenz tetra dovrebbe essere basato su raccomandazioni ufficiali.

Liên Minh Châu Âu - Tiếng Ý - EMA (European Medicines Agency)

astrazeneca ab - palivizumab - infezioni da virus respiratorio sinciziale - sieri immuni e immunoglobuline, - synagis è indicato per la prevenzione di gravi inferiore-respiratorio, del tratto di malattia che richiedono ospedalizzazione, provocate dal virus respiratorio sinciziale (rsv) in bambini ad alto rischio per la malattia di rsv:bambini nati a 35 settimane di gestazione o meno e di meno di sei mesi di età all'esordio della stagione critica;i bambini di meno di due anni di età e che necessitano di un trattamento per la displasia broncopolmonare negli ultimi sei mesi;i bambini di meno di due anni di età e con haemodynamically significativa malattia di cuore congenita.

Liên Minh Châu Âu - Tiếng Ý - EMA (European Medicines Agency)

astrazeneca ab - osimertinib mesilate - carcinoma, polmone non a piccole cellule - altri agenti antineoplastici, inibitori della proteina chinasi - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.

Liên Minh Châu Âu - Tiếng Ý - EMA (European Medicines Agency)

astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - malattia polmonare, ostruttiva cronica - farmaci per le malattie respiratorie ostruttive, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.

Liên Minh Châu Âu - Tiếng Ý - EMA (European Medicines Agency)

astrazeneca ab - moxetumomab pasudotox - leucemia, hairy cell - agenti antineoplastici - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).

Liên Minh Châu Âu - Tiếng Ý - EMA (European Medicines Agency)

astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - agenti antineoplastici - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.

Liên Minh Châu Âu - Tiếng Ý - EMA (European Medicines Agency)

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - malattia polmonare, ostruttiva cronica - farmaci per le malattie respiratorie ostruttive, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.

Liên Minh Châu Âu - Tiếng Ý - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - agenti antineoplastici - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.